We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Synergistic Protection: Combining GLP-1 Receptor Agonists with Lifestyle Habits Slashes Cardiovascular Risk in Type 2 Diabetes

MedXY Editorial Team•Mar 7, 2026•Cardiology
cardiovascular riskGLP-1 receptor agonistslifestyle medicinetype 2 diabetes

Highlights

The integration of GLP-1 receptor agonists (GLP-1RAs) with high adherence to eight healthy lifestyle habits is associated with a 43% lower risk of Major Adverse Cardiovascular Events (MACE) compared to those with poor lifestyle habits and no GLP-1RA use.

While GLP-1RAs independently reduced MACE risk by 16%, adhering to all eight low-risk lifestyle habits provided a staggering 60% reduction in risk compared to adhering to one or fewer habits.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World DataFenofibrate use in type 2 diabetes patients is associated with a significant reduction in the risk of sight-threatening diabetic retinopathy compared to statins, based on UK primary care data over 12 years.Sep 18, 2026Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative AnalysisAmong type 2 diabetes patients using GLP-1 receptor agonists, oxycodone is linked to higher short-term risks of severe gastrointestinal complications compared to hydrocodone and tramadol, warranting cautious opioid selection in this populatSep 15, 2026Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Illuminating the Night: How Nighttime Light Exposure Impacts Cardiac Structure, Function, and Cardiovascular Risk
Nighttime light exposure over 3 lux is linked to adverse cardiac remodeling, subclinical functional decline, and increased cardiovascular events, partly mediated by shorter sleep duration, underscoring the importance of dark nights and slee
Sep 15, 2026
Common Anti-Inflammatory Drugs Linked to Lower Risk of Vision-Threatening Diabetic Retinopathy in Type 2 DiabetesA large retrospective cohort study suggests that cetirizine, ibuprofen, and prednisone use in adults with type 2 diabetes is associated with significantly reduced incidence of diabetic macular edema and proliferative diabetic retinopathy, hSep 15, 2026
Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms: Insights from the SWAN StudyInitiation of menopausal hormone therapy during perimenopause or early postmenopause in women with vasomotor symptoms is associated with a reduced cardiovascular risk, especially among Black women and those starting therapy within 10 yearsSep 13, 2026